/Gilead%20Sciences%2C%20Inc_%20logo%20and%20vials%20-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Foster City, California-based Gilead Sciences, Inc. (GILD) discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States and internationally. The company has a market cap of $173 billion and provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for the treatment of HIV-1 infection in patients, as well as other related drugs.
GILD is expected to release its Q1 2026 earnings soon. Ahead of the event, analysts expect the company’s EPS to be $1.86 on a diluted basis, up 2.8% from $1.81 in the year-ago quarter. The company has exceeded Wall Street’s EPS estimates in three of its last four quarters, while missing the mark once.